

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/847,513	DELONG ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Teresa E. Strzelecka	1637

**All Participants:**

**Status of Application:** Pending

(1) Teresa E. Strzelecka.

(3) \_\_\_\_\_.

(2) Miriam Kaplan.

(4) \_\_\_\_\_.

**Date of Interview:** 30 June 2006

**Time:** \_\_\_\_\_

**Type of Interview:**

- Telephonic  
 Video Conference  
 Personal (Copy given to:  Applicant     Applicant's representative)

**Exhibit Shown or Demonstrated:**  Yes     No

If Yes, provide a brief description:

#### **Part I.**

Rejection(s) discussed:

Claims discussed:

42, 44

Prior art documents discussed:

#### **Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

#### **Part III.**

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Teresa Strzelecka

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Ms. Kaplan was contacted because the newly amended claims 42 and 44 were not allowable, reading on any cell membrane. Ms. Kaplan agreed to add the limitation "comprising the proteorhodopsin protein of claim 1" to claims 42 and 44, putting the application in condition for allowance..